Bupropion and naltrexone are pharmacologically active agents used together as weight-management and smoking-cessation therapy. The combination exploits bupropion's action as a norepinephrine-dopamine reuptake inhibitor and naltrexone's antagonism of opioid receptors to influence appetite regulation. Pharmacodynamically, bupropion increases dopaminergic activity in the hypothalamus enhancing satiety signals while reducing reward-associated cravings. Concurrently, naltrexone attenuates the reinforcing effects of food and nicotine by blocking endogenous mu opioid receptors, leading to decreased hedonic drive. The net effect stems from synergistic modulation of central neurotransmission pathways that together lower caloric intake and support abstinence from smoking. This dual mechanism results in a measurable reduction in body weight and cessation rates in clinical trials without central nervous system stimulation beyond normal dopaminergic tone.

Bupropion combined with naltrexone is a fixed-dose dual-acting medication used primarily in the management of obesity and certain eating-related disorders. The formulation combines a norepinephrine-dopamine reuptake inhibitor with an opioid receptor antagonist to target central pathways that regulate appetite and reward. By inhibiting the reuptake of norepinephrine and dopamine the drug enhances signaling in the hypothalamic and mesolimbic circuits that influence satiety and motivation. Naltrexone blocks mu opioid receptors, reducing the perceived rewarding effects of food and decreasing hedonic drive. Together they produce a synergistic modulation of neural circuits that leads to reduced caloric intake and modest weight loss when used alongside lifestyle interventions. The pharmacokinetic profile of the combination allows prolonged plasma exposure, which sustains therapeutic effects throughout the dosing interval. Metabolism occurs mainly through hepatic pathways, with the agents influencing each other's clearance in a way that maintains steady concentrations. Clinical studies have demonstrated that this pharmacodynamic synergy translates into measurable improvements in body weight and metabolic parameters in appropriate patient populations.

Insomnia difficulty sleeping may occur when using the combination. Dry mouth can be experienced by some patients. Headache is reported as a common side effect. Dizziness or lightheadedness may appear occasionally. Nausea or stomach discomfort can develop. Constipation may affect some individuals. An increase in heart rate can be observed during treatment. Changes in appetite may also be noted as the medication influences weight regulation.

Bupropion and naltrexone are sometimes used together for weight management. Common side effects include dry mouth and insomnia. Nausea and headache are also frequently reported. Patients may experience dizziness or sleep disturbances. Mood changes such as anxiety or irritability can occur. Rarely, changes in blood pressure or heart rate may be observed. These effects are generally mild but can vary among individuals.